Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SGLT 2 Inhibitors”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableNot Yet RecruitingNCT07472920
What this trial is testing

Empagliflozin Adjunctive Therapy in Bipolar Depression

Who this might be right for
Bipolar DisorderBipolar DepressionInsulin Resistance
University of Sao Paulo 20
Large-scale testing (Phase 3)Study completedNCT03723252
What this trial is testing

Dapagliflozin Efficacy and Action in NASH

Who this might be right for
Nonalcoholic Steatohepatitis
Nanfang Hospital, Southern Medical University 154
Early research (Phase 1)Study completedNCT01512849
What this trial is testing

Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Who this might be right for
Type 2 Diabetes Mellitus
Tanabe Pharma Corporation 24
Not applicableActive Not RecruitingNCT07204743
What this trial is testing

Efficacy and Safety of Dapagliflozin in Children With Proteinuria

Who this might be right for
SGLT 2 InhibitorsPediatric Kidney DiseaseProteinuric Diseases+1 more
Al-Quds University 10
Large-scale testing (Phase 3)Study completedNCT06109311
What this trial is testing

Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor

Who this might be right for
Type 2 Diabetes
Eli Lilly and Company 546
Post-approval studies (Phase 4)Not Yet RecruitingNCT07342764
What this trial is testing

Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial

Who this might be right for
Antipsychotic-induced Weight Gain (AIWG)Antipsychotic-induced Weight Gain
Sultan Qaboos University 110
Not applicableActive Not RecruitingNCT06901609
What this trial is testing

Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients

Who this might be right for
Heart Failure - NYHA II - IVCardiac FibrosisCardiac Remodeling
Ain Shams University 200
Post-approval studies (Phase 4)Study completedNCT05309785
What this trial is testing

Safety and Efficacy of Canagliflozin in Advanced CKD

Who this might be right for
ESRDCKD Stage 4CKD Stage 5
McGill University Health Centre/Research Institute of the McGill University Health Centre 34
Not applicableActive Not RecruitingNCT07063316
What this trial is testing

SGLT2 Inhibitors and Renal Anemia in Japan: RWD

Who this might be right for
Chronic Kidney Disease
Boehringer Ingelheim 15,000
Post-approval studies (Phase 4)Study completedNCT04447911
What this trial is testing

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

Who this might be right for
HyponatremiaSIADHLiver Failure+1 more
University Hospital, Basel, Switzerland 113
Large-scale testing (Phase 3)Active Not RecruitingNCT05182658
What this trial is testing

Empagliflozin in Hypertrophic Cardiomyopathy

Who this might be right for
Hypertrophic CardiomyopathyHeart Failure
National Institute of Cardiology, Warsaw, Poland 250
Post-approval studies (Phase 4)Study completedNCT06383832
What this trial is testing

Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet.

Who this might be right for
OverweightCarbohydrateSodium-glucose Transporter 2 Inhibitors
Sun Jia 36
Post-approval studies (Phase 4)Looking for participantsNCT07572032
What this trial is testing

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Who this might be right for
Heart Failure Due to Coronary Artery DiseaseValvular CardiomyopathyHeart Failure
Kyungsub Song 80
Large-scale testing (Phase 3)Looking for participantsNCT07653477
What this trial is testing

Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)

Who this might be right for
Type 2 Diabetes
The United Bio-Technology (Hengqin) Co., Ltd. 956
Early research (Phase 1)Study completedNCT06828731
What this trial is testing

Evaluation of Empagliflozin vs Standard Care in Veterans With Prediabetes

Who this might be right for
Prediabetes
Charles George VA Medical Center 60
Post-approval studies (Phase 4)Study completedNCT05057819
What this trial is testing

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Who this might be right for
Dumping SyndromeHypoglycemia, Reactive
Insel Gruppe AG, University Hospital Bern 22
Post-approval studies (Phase 4)UnknownNCT03573102
What this trial is testing

Effect of Sodium Glucose co Transporter 2 Inhibitor ( SGLT2) on Proteinuria in Diabetic Patients

Who this might be right for
Diabetic Nephropathies
Nahla H Tohami 60
Large-scale testing (Phase 3)Study completedNCT02729766
What this trial is testing

Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study

Who this might be right for
Inappropriate ADH Syndrome
University Hospital, Basel, Switzerland 15
Not applicableStudy completedNCT06951737
What this trial is testing

Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients

Who this might be right for
Diabetes MellitusAtrial Fibrillation (AF)
Bursa Postgraduate Hospital 120
Testing effectiveness (Phase 2)Study completedNCT05884866
What this trial is testing

Investigate the Mechanistic Effects of Dapagliflozin Alone or in Combination With Balcinrenone, Compared to Balcinrenone and Placebo on Body Fluid and Electrolyte Handling and Energy Metabolism in Participants Over 50 Years of Age With Chronic Kidney Disease.

Who this might be right for
Chronic Renal FailureMechanistic Effects of SGLT2 Inhibition and/ or MR Antagonism on Body Fluid and Electrolyte HomeostatisChronic Kidney Disease Stage 3+1 more
Klinikum Nürnberg
Next Page
103